首页> 外文期刊>Expert opinion on biological therapy >Recent advances in the biologic therapy of lupus: the 10 most important areas to look for common pitfalls in clinical trials
【24h】

Recent advances in the biologic therapy of lupus: the 10 most important areas to look for common pitfalls in clinical trials

机译:狼疮生物疗法的最新进展:寻找临床试验中常见陷阱的10个最重要领域

获取原文
获取原文并翻译 | 示例
           

摘要

Introduction: Systemic lupus erythematosus (SLE) is an autoimmune disease affecting different organs. The improved knowledge of the disease's pathogenesis has contributed to the emergence of immune targets and new biologic drugs directed at them. Although rheumatologists continue to use off-label biologics in SLE resistant to other immunosuppressants, only belimumab has been approved as a biological therapy since 2011.
机译:简介:系统性红斑狼疮(SLE)是一种影响不同器官的自身免疫性疾病。对疾病发病机理的了解增加,促进了免疫靶标和针对它们的新生物药物的出现。尽管风湿病学家在抗其他免疫抑制剂的SLE中继续使用标签外生物制剂,但自2011年以来,只有贝利木单抗才被批准为生物疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号